Yield10 Bioscience Inc (NASDAQ:YTEN) has earned an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Brokerages have set a 12 month consensus price target of $5.00 for the company, according to Zacks. Zacks has also given Yield10 Bioscience an industry rank of 237 out of 255 based on the ratings given to its competitors.
A number of equities analysts have recently issued reports on YTEN shares. Aegis reissued a “buy” rating and set a $2.00 price objective on shares of Yield10 Bioscience in a research report on Tuesday, August 13th. National Securities reissued a “buy” rating and set a $5.00 price objective on shares of Yield10 Bioscience in a research report on Tuesday, August 20th. Finally, Zacks Investment Research reissued a “hold” rating on shares of Yield10 Bioscience in a research report on Saturday, October 19th.
A hedge fund recently raised its stake in Yield10 Bioscience stock. Renaissance Technologies LLC increased its holdings in Yield10 Bioscience Inc (NASDAQ:YTEN) by 9.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 478,176 shares of the specialty chemicals company’s stock after acquiring an additional 41,500 shares during the period. Renaissance Technologies LLC owned about 3.83% of Yield10 Bioscience worth $463,000 at the end of the most recent quarter. Institutional investors own 7.69% of the company’s stock.
YTEN traded down $0.05 during trading on Monday, reaching $0.50. 207,500 shares of the stock traded hands, compared to its average volume of 140,198. The company has a quick ratio of 3.33, a current ratio of 3.33 and a debt-to-equity ratio of 1.17. The stock has a market capitalization of $7.49 million, a PE ratio of -0.54 and a beta of 3.15. The stock’s 50-day moving average is $0.62 and its 200 day moving average is $0.86. Yield10 Bioscience has a 12 month low of $0.48 and a 12 month high of $1.77.
Yield10 Bioscience (NASDAQ:YTEN) last released its quarterly earnings data on Monday, August 12th. The specialty chemicals company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.06. The company had revenue of $0.32 million for the quarter. Yield10 Bioscience had a negative net margin of 1,320.21% and a negative return on equity of 145.61%. As a group, equities research analysts anticipate that Yield10 Bioscience will post -0.66 EPS for the current year.
About Yield10 Bioscience
Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield.
Featured Story: Convertible Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.